Samsung Biologics, AstraZeneca enter into global supply partnership
South Korean biotechnology firm Samsung Biologics and UK-based pharmaceutical firm AstraZeneca have signed a long-term supply agreement, worth around $330.8m. Under the terms of the agreement, Samsung Biologics